Related references
Note: Only part of the references are listed.Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
Florian Malchers et al.
CANCER DISCOVERY (2014)
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Rachel G. Liao et al.
CANCER RESEARCH (2013)
Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer
Hye Ryun Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma
Kenneth J. Craddock et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
R. C. Doebele et al.
ANNALS OF ONCOLOGY (2012)
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
R. J. Young et al.
BRITISH JOURNAL OF CANCER (2012)
Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Jingchuan Zhang et al.
CLINICAL CANCER RESEARCH (2012)
FIBROBLAST GROWTH FACTOR 2-A PREDICTOR OF OUTCOME FOR PATIENTS IRRADIATED FOR STAGE II-III NON-SMALL-CELL LUNG CANCER
Dirk Rades et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer
Isamu Okamoto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial
Pavel Nemec et al.
LEUKEMIA & LYMPHOMA (2012)
MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer
Tom Donnem et al.
PLOS ONE (2012)
FGFR1 expression and gene copy numbers in human lung cancer
Lukas H. Kohler et al.
VIRCHOWS ARCHIV (2012)
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
A. Kalff et al.
BLOOD CANCER JOURNAL (2012)
Fibroblast growth factors and their receptors in cancer
Jorgen Wesche et al.
BIOCHEMICAL JOURNAL (2011)
Preclinical evaluation of the novel multi-targeted agent R1530
Kenneth Kolinsky et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo
Zhi-Xing Cao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2011)
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events
Reza R. Serizawa et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features
Tokujiro Yano et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
Mei Zhao et al.
LUNG CANCER (2011)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Amit Dutt et al.
PLOS ONE (2011)
8p11 myeloproliferative syndrome: a review
Courtney C. Jackson et al.
HUMAN PATHOLOGY (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
Sheldon R. Mink et al.
MOLECULAR CANCER RESEARCH (2010)
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier et al.
PLOS ONE (2010)
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
Kathryn E. Ware et al.
PLoS One (2010)
Mutational Activation of FGFR3 is Not Involved in the Development of Prostate Cancer
Stella Koufou et al.
PATHOBIOLOGY (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Drug Development for Cancer Chemoprevention: Focus on Molecular Targets
Karen A. Johnson et al.
SEMINARS IN ONCOLOGY (2010)
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
Scott A. Kono et al.
DRUG RESISTANCE UPDATES (2009)
Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer Results from JMTO LC 0004
Shun-Ichi Isa et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy
Sigve Andersen et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival
Tom Donnem et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Michael G. Gartside et al.
MOLECULAR CANCER RESEARCH (2009)
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip
Annie Chou et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2009)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Lindsay Marek et al.
MOLECULAR PHARMACOLOGY (2009)
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation
Sara A. Byron et al.
CANCER RESEARCH (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an eastern cooperative oncology group study
Afshin Dowlati et al.
CLINICAL CANCER RESEARCH (2008)
Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer
Carmen Behrens et al.
CLINICAL CANCER RESEARCH (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Hendrik Fischer et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4
Jenifer L. Marks et al.
PLOS ONE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines
Hartmut Kuhn et al.
LUNG CANCER (2006)
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T
Manickam Muruganandham et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
Silvia Hernandez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
RM Bremnes et al.
LUNG CANCER (2006)
Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma
ALS Tai et al.
CANCER (2006)
Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors
K Zieger et al.
CLINICAL CANCER RESEARCH (2005)
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
JMM van Oers et al.
CLINICAL CANCER RESEARCH (2005)
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
V Rand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer
C Müller-Tidow et al.
CANCER RESEARCH (2005)
Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival
AZ Dudek et al.
CANCER INVESTIGATION (2005)
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens
H Wallerand et al.
CARCINOGENESIS (2005)
Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines
H Kuhn et al.
LUNG CANCER (2004)
Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC
A Iwasaki et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2004)
Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer
D Brattstrom et al.
LUNG CANCER (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression
M Beau-Faller et al.
EUROPEAN JOURNAL OF CANCER (2003)
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
BWG van Rhijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
BWG van Rhijn et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2002)
Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients
D Brattström et al.
LUNG CANCER (2002)
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer
Y Shou et al.
BRITISH JOURNAL OF CANCER (2001)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
D Intini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al.
ONCOGENE (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis
K Ueno et al.
LUNG CANCER (2001)
Share Paper
